Home › Acute Myeloid Leukemia › Nebraska › Omaha
Acute Myeloid Leukemia clinical trials in Omaha, NE
10 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Omaha (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi away
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi away
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi away
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecruitingPhase 3
- Children's Hospital and Medical Center of Omaha, Omaha
- University of Nebraska Medical Center, Omaha
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Children's Hospital and Medical Center of Omaha, Omaha
- University of Nebraska Medical Center, Omaha
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- University of Nebraska Medical Center, Omaha
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
RecruitingPhase 2/3
- University of Nebraska Medical Center, Omaha
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- University of Nebraska Medical Center, Omaha
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RecruitingPhase 1/2
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX88 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Baldwin Park, CA41 studies
- Seattle, WA40 studies
- Durham, NC34 studies
- Columbus, OH34 studies
- Philadelphia, PA33 studies
- Atlanta, GA30 studies
- Tampa, FL30 studies
- Chicago, IL27 studies
- Los Angeles, CA25 studies
Other studies in Omaha
- Prostate Cancer29 studies
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer23 studies
- Cancer (all types)19 studies
- Colorectal Cancer18 studies
- Multiple Myeloma17 studies
- Ovarian Cancer15 studies
- Pancreatic Cancer15 studies
- Head and Neck Squamous Cell Carcinoma15 studies
- Metastatic Cancer14 studies
- Non-Hodgkin Lymphoma14 studies
- Lung Cancer13 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.